On Thursday, 2637 stocks advanced, 1327 declined and 151 remained unchanged on Bombay Stock Exchange with advance decline ratio of 1.99 indicating a positive closing in the broader market. The trend of the major indices on Thursday’s trading is given in the table below.
On NSE, 26 securities advanced and closed at a new 52-week high whereas 52 securities sank to close at their new 52-week lows. All sectoral indices ended in green, Nifty Auto, Nifty Metal and Nifty Media were among the biggest gainers.
Lupin (+0.07%) received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP. These tablets are bioequivalent to Janssen Pharmaceuticals Xarelto Tablets and will be manufactured at Lupin's facility in Aurangabad, India. Rivaroxaban is indicated for various uses, including reducing the risk of stroke and embolism. Xarelto's estimated annual sales in the US were approximately $8.05 billion as of March 2025. Lupin had previously received tentative approval for the 2.5 mg dosage of Rivaroxaban Tablets USP in January 2024 and launched it in the US market in March 2025.
Infosys (+1.29%), a global leader in digital services, expanded its strategic collaboration with DNB Bank ASA, Norway's largest bank. This partnership aims to accelerate DNB's digital transformation by modernizing its IT landscape, improving operational efficiency, and enhancing customer experience.
Alembic Pharmaceuticals (+0.76%) received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets.
Cochin Shipyard Limited (CSL) (+6.63%) addressed recent media reports suggesting talks with Hyundai for a Rs10,000 crore ($1.2 billion) shipbuilding project. CSL clarified that while they are evaluating various opportunities for shipbuilding and ship repair aligned with government initiatives like the Maritime India Vision 2030 and Maritime Amrit Kaal Vision 2047, there is currently no material event requiring disclosure regarding any specific deal, including one with Hyundai.
Shilpa Medicare's (+2.88%) wholly-owned subsidiary, Shilpa Pharma Lifesciences Limited (SPL), received a favorable inspection report (EIR) from the US Food and Drug Administration (USFDA) for its Unit-I facility. The inspection resulted in the site being classified as voluntary action indicated (VAI). This classification suggests that while some objectionable conditions were noted during the inspection, they are not considered to be of a nature that would require immediate regulatory action, allowing the facility to continue its operations and supply products to the US market.
In Q4FY24-25, Thangamayil Jewellery (-4.89%) sales increased by 40% y-o-y to Rs1,381 crore, while operating profit increased by 15% y-o-y to Rs57.4 crore and net profit increased by 11% y-o-y to Rs31.4 crore.
In Q4FY24-25, Caplin Point Lab (-0.73%) sales increased by 11% y-o-y to Rs502 crore, while operating profit increased by 16% y-o-y to Rs168 crore and Net profit increased by 18% y-o-y to Rs145 crore.
In Q4FY24-25, Lupin’s sales increased by 14% y-o-y to Rs5,667 crore, while operating profit increased by 33% y-o-y to Rs1,321 crore and Net profit increased by 115% y-o-y to Rs782 crore.
In Q4FY24-25, Tilaknagar Industries (+14.11%) sales increased by 13% y-o-y to Rs406 crore, while operating profit increased by 63% y-o-y to Rs78.4 crore and Net profit increased by 96% y-o-y to Rs77.4 crore.
In Q4FY24-25, Piramal Pharma (-4.76%) sales increased by 8% y-o-y to Rs2,754 crore, while operating profit increased by 6% y-o-y to Rs561 crore and Net profit increased by 34% y-o-y to Rs154 crore.
In Q4FY24-25, BLS E-Services (+14.65%) sales increased by 225% y-o-y to Rs239 crore, while operating profit increased by 78% y-o-y to Rs19.4 crore and Net profit increased by 28% y-o-y to Rs17.3 crore.
In Q4FY24-25, Sagility India (-4.48%) sales increased by 22% y-o-y to Rs1,568 crore, while operating profit increased by 21% y-o-y to Rs373 crore and Net profit increased by 128% y-o-y to Rs183 crore.
The top gainers and top losers of the major indices are given in the table below:
The closing values of the major Asian indices are given in the table below:
